Decitabine
Links shared publicly online about this topic
Eisai Announces Results Of Phase III Study Of Dacogen(R) (Decitabine) For Injection In Acute Myeloid Leukemia (AML)
medicalnewstoday.com — “Eisai Inc. announced preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in eld” View full resource at medicalnewstoday.com
Most Recently Shared on July 4, 2010 at 12:04 pm By:
Eisai Announces Results Of Phase III Study Of Dacogen(R) (Decitabine) For Injection In Acute Myeloid Leukemia (AML) http://mnt.to/3FHb
Clinical trial - Treatment with decitabine and peg-interferon for advanced melanoma - http://bit.ly/eHsvgq (PDF)
physicianrelations.org — “Clinical trial - Treatment with decitabine and peg-interferon for advanced melanoma - http://bit.ly/eHsvgq (PDF)” View full resource at physicianrelations.org
Most Recently Shared on January 21, 2011 at 10:55 pm By:
Physician Relations Health Organization
Clinical trial - Treatment with decitabine and peg-interferon for advanced melanoma - http://bit.ly/eHsvgq (PDF)
Phase 1 study of epigenetic priming with decitabine pr... [Blood. 2011] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on August 27, 2011 at 11:14 pm By:
G Garcia-Manero Internist, Oncologist, Physician, and Doctor
decitabine priming of induction therapy in AML. Here the investigators provide a course of decitabine prior to... http://t.co/Xkur0gf
Decitabine Found to Be Safe, Effective in Patients With Myelodysplastic Syndrome Failing Prior Intensive Regimen - ONA
oncologynurseadvisor.com — “Patients with myelodysplastic syndrome (MDS) previously treated with intensive regimens had responses to decitabine similar to those who were treatment-nave, suggesting this population should be considered for this hypomethylating therapy, results of a retrospective analysis have found. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 6, 2010 at 7:54 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Decitabine Found to Be Safe, Effective in Patients With Myelodysplastic Syndrome Failing… http://goo.gl/fb/KN1P8
In Older AML Patients, Decitabine Showed Survival Advantage Over Standard Therapies - ONA
oncologynurseadvisor.com — “In a Phase 3, multicenter trial involving patients ?65 years who were newly diagnosed with de novo or secondary acute myeloid leukemia, decitabine demonstrated an overall survival advantage over standard therapies, according to data presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 6, 2011 at 4:55 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
In Older AML Patients, Decitabine Showed Survival Advantage Over Standard Therapies http://goo.gl/fb/uMwhg
In Older AML Patients, Decitabine Showed Survival Advantage Over Standard Therapies - MPR
empr.com — “In a Phase 3, multicenter trial involving patients ?65 years who were newly diagnosed with de novo or secondary acute myeloid leukemia, decitabine demonstrated an overall survival advantage over standard therapies, according to data presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 6, 2011 at 5:38 pm By:
#asco2011 In Older AML Patients, Decitabine Showed Survival Advantage Over Standard Therapies http://goo.gl/fb/qt7vw
Phase I study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
bloodjournal.hematologylibrary.org — “Phase I study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML” View full resource at bloodjournal.hematologylibrary.org
Most Recently Shared on June 7, 2011 at 12:45 am By:
G Garcia-Manero Internist, Oncologist, Physician, and Doctor
http://bloodjournal.hematologylibrary.org/content/early/2011/05/25/blood-2010-11-320093.abstract?sid=0f710bb2-a331-418a-8877-2ae71042d9b3
Phase III Study of Dacogen (decitabine) for Injection in Acute Myeloid Leukemia (AML) Presented at ASCO - Drugs.com MedNews
drugs.com — “Jun 6, 2011 - Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the Ame” View full resource at drugs.com
Most Recently Shared on June 6, 2011 at 6:13 pm By:
Drugs and Devices OW OW Health
Phase III Study of Dacogen (decitabine) for Injection in Acute Myeloid Leukemia (AML) Presented at ASCO: C... http://bit.ly/lzMcjU #drug
FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
drugs.com — “Dacogen (decitabine) is used to treat Myelodysplastic Syndromes. Includes Dacogen side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on March 16, 2010 at 12:27 am By:
FDA Approves Five-Day Dosing Regimen for Dacogen, Offering a New Outpatient Dosing Option - http://bit.ly/d7TGFP
Eisai and Janssen Announce the Presentation of DACOGEN (decitabine) Data at ASCO from a Phase III Study in Patients with Acute Myeloid Leukemia - Drugs.com MedNews
drugs.com — “Data from DACO-016 study at 2011 American Society of Clinical Oncology Annual Meeting Jun 6, 2011 - Eisai Inc. and Janssen, a Johnson Johnson Company, both anno” View full resource at drugs.com
Most Recently Shared on June 6, 2011 at 8:10 pm By:
Drugs and Devices OW OW Health
Eisai and Janssen Announce the Presentation of DACOGEN (decitabine) Data at ASCO from a Phase III Study in... http://bit.ly/jtD82V #drug
Oncology Medical Article | Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
mdlinx.com — “Oncology Medical Article: Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients” View full resource at mdlinx.com
Most Recently Shared on March 13, 2012 at 6:48 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with... http://t.co/JUscp55W #oncology
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Rese
jco.ascopubs.org — “Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group” View full resource at jco.ascopubs.org
Most Recently Shared on May 22, 2011 at 2:27 pm By:
JanCerny, MD, PhD Hematologist, Physician, Doctor, PhD, Internist, and Oncologist
LD-decitabine improves outcomes in elderly int and high risk MDS iIneligible for intensive chemotherapy: Phase III study http://ow.ly/509Ww
Cyclacel drug promising in myelodysplastic syndrome
health.yahoo.net — “Nearly a third of patients with the blood cancer myelodysplastic syndrome who were not helped by prior treatment survived for one year after taking an experimental drug being developed by Cyclacel Pharmaceuticals Inc, according to data from a mid-stage study.” View full resource at health.yahoo.net
Most Recently Shared on December 4, 2010 at 11:40 pm By:
Cyclacel drug promising in myelodysplastic syndrome http://bit.ly/g3yej8
Cyclacel drug promising in myelodysplastic syndrome
health.yahoo.net — “Nearly a third of patients with the blood cancer myelodysplastic syndrome who were not helped by prior treatment survived for one year after taking an experimental drug being developed by Cyclacel Pharmaceuticals Inc, according to data from a mid-stage study.” View full resource at health.yahoo.net
Most Recently Shared on December 4, 2010 at 11:04 pm By:
Jane Anderson Healthy Eating Advisor
Cyclacel drug promising in myelodysplastic syndrome http://bit.ly/gWTESD
Cyclacel drug promising in myelodysplastic syndrome
health.yahoo.net — “Nearly a third of patients with the blood cancer myelodysplastic syndrome who were not helped by prior treatment survived for one year after taking an experimental drug being developed by Cyclacel Pharmaceuticals Inc, according to data from a mid-stage study.” View full resource at health.yahoo.net
Most Recently Shared on December 4, 2010 at 11:17 pm By:
Jennifer Ann Grisso Nurse and Active Health Library
Cyclacel drug promising in myelodysplastic syndrome: Nearly a third of patients with the blood cancer myelodyspl... http://bit.ly/fFJFWj
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
MNT Leukemia
The latest lymphoma and leukemia news published daily. Articles from research centers, universities and prestigious journals.
-
Physician Relations
Everything you need to know about MD Anderson cancer research, treatment, education and patient care is available through the Office of Physician Relations.
-
G Garcia-Manero
Leukemia physician and Professor of Medicine and Chief of Section of MDS at MD Anderson Cancer Center. Leukemia, Books, maybe some other staff.
Advertisement
